Dialectic Therapeutics
Manufacturing · Texas, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
3889 Maple Ave Ste 125, Dallas, Texas, 7...Phone Number
(972) 525-1499Website
www.dtsciences.comRevenue
<$5 MillionIndustry
About Dialectic Therapeutics
Dialectic Therapeutics is a biotechnology company focused on developing innovative anti-cancer drugs, particularly targeting patients with limited treatment options. Their lead product, DT2216, is designed to induce cancer cell death by degrading the BCL-XL protein, and is currently in clinical trials for various cancers. The company aims to provide hope and improve the quality of life for cancer patients through targeted therapies with minimal side effects. Based in Dallas, Texas, Dialectic collaborates with leading research institutions to advance its therapeutic candidates.Explore more
Dialectic Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Dialectic Therapeutics
Compare insights from companies similar to Dialectic Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Dialectic Therapeutics Tech Stack
A closer look at the technologies used by Dialectic Therapeutics
See more technologies
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Dialectic Therapeutics
Sign Up For FreeTo access detailed company insights
Dialectic Therapeutics is a biotechnology company focused on developing innovative anti-cancer drugs, particularly targeting patients with limited treatment options. Their lead product, DT2216, is designed to induce cancer cell death by degrading the BCL-XL protein, and is currently in clinical trials for various cancers. The company aims to provid... Read More
